Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15339919 | 0.86 | ERN1 (0.37) | ERN1CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1197434 | 0.82 | CYP2C9 (0.45) | ERN1CYP2C9CYP3A4CYP2C19PTGS2 | |
| SCHEMBL31685229 | 0.80 | CYP2C9 (0.46) | ERN1CYP2C9CYP3A4CYP2C19PTGS2 | |
| SCHEMBL415893 | 0.80 | CYP2C9 (0.46) | ERN1CYP2C9CYP3A4CYP2C19PTGS2 | |
| SCHEMBL24677699 | 0.78 | ERN1 (0.46) | ERN1CYP3A4PTGS2ALDH1A1 | |
| SCHEMBL14691491 | 0.78 | ALDH1A1 (0.41) | ERN1PTGS2PTGS1ALDH1A1TSHR | |
| SCHEMBL1678780 | 0.78 | ERN1 (0.48) | ERN1CYP3A4ALDH1A1 | |
| SCHEMBL19792394 | 0.78 | ERN1 (0.38) | ERN1ALDH1A1TSHR | |
| SCHEMBL14448986 | 0.78 | ERN1 (0.36) | ERN1CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL12384956 | 0.77 | ERN1 (0.38) | ERN1CYP2C9CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018048969-A1 | MULTI-TARGETED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-03-15 | — | — | WO | disclosed |
| US-8664411-B2 | Tetrahydropyranochromene gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2421866-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110236400-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION | 2011-09-29 | — | — | US | disclosed |
| EP-2235017-B1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-09-14 | — | — | EP | disclosed |
| EP-1996591-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-1996591-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| WO-2010121995-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007104714-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104714-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104664-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104664-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | ERN1 974/4885CYP2C9 1445/4885CYP3A4 756/4885 |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | SIK3, RB1, CCND3 | ERN1 1293/4885CYP2C9 3601/4885CYP3A4 2589/4885 |
| US-20070213341-A1 | Spiroindolinone derivatives | MKI67, PKD1, RCC2 | ERN1 2299/4885CYP2C9 1049/4885CYP3A4 407/4885 |
| US-20110236400-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, APP | ERN1 1941/4885CYP2C9 1287/4885CYP3A4 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.